Sangamo Therapeutics (SGMO) News Today

→ Biden’s $374B Giveaway Into This Sector (From DTI) (Ad)

$0.49

-0.03 (-5.82%)

(As of 04/18/2024 ET)

Source

Source	Headline
	Biotech Roundtable: Who will bring the next CRISPR drug to market? msn.com - April 2 at 11:56 AM
	Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Receives Consensus Recommendation of "Hold" from Brokerages marketbeat.com - March 29 at 4:26 AM
	Sangamo Therapeutics (NASDAQ:SGMO) Share Price Passes Above 200-Day Moving Average of $0.62 marketbeat.com - March 29 at 2:31 AM
	What You Need To Know About The Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Analyst Downgrade Today finance.yahoo.com - March 25 at 10:26 PM
	Q1 2024 Earnings Estimate for Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Issued By HC Wainwright marketbeat.com - March 21 at 8:02 AM
	Sangamo Therapeutics Inc money.usnews.com - March 19 at 6:57 PM
	Sangamo Therapeutics (NASDAQ:SGMO) Given "Buy" Rating at HC Wainwright marketbeat.com - March 19 at 8:34 AM
	Sangamo Therapeutics' (SGMO) Sector Perform Rating Reaffirmed at Royal Bank of Canada marketbeat.com - March 18 at 5:11 PM
	Q1 2024 Earnings Estimate for Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Issued By Wedbush marketbeat.com - March 18 at 1:27 AM
	SGMO Apr 2024 1.500 put ca.finance.yahoo.com - March 16 at 11:33 PM
	Analysts Conflicted on These Healthcare Names: Veradigm (OtherMDRX), ADC Therapeutics (ADCT) and Sangamo Biosciences (SGMO) markets.businessinsider.com - March 16 at 8:32 AM
	SGMO Apr 2024 1.500 call finance.yahoo.com - March 16 at 3:31 AM
	SGMO Apr 2024 3.000 call finance.yahoo.com - March 15 at 10:29 PM
	Sangamo Therapeutics Full Year 2023 Earnings: Misses Expectations finance.yahoo.com - March 14 at 4:24 PM
	Sangamo Biosciences’ Breakthrough Capsid Technology Spurs Buy Rating markets.businessinsider.com - March 13 at 8:10 PM
	4 Analysts Assess Sangamo Therapeutics: What You Need To Know markets.businessinsider.com - March 13 at 8:10 PM
	Sangamo Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results businesswire.com - March 13 at 8:05 AM
	Sangamo Therapeutics Announces Fourth Quarter and Full Year 2023 Conference Call and Webcast businesswire.com - March 12 at 6:30 PM
	Sangamo Therapeutics, Inc. (SGMO) finance.yahoo.com - March 1 at 9:22 AM
	Sangamo Therapeutics (SGMO) Earnings Dates & Reports investing.com - February 23 at 7:58 PM
	Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Sees Significant Growth in Short Interest marketbeat.com - February 17 at 3:10 AM
	Sangamo Biosciences: Hold Rating Amid Regulatory Progress and Financial Uncertainties markets.businessinsider.com - February 13 at 1:56 PM
	Sangamo Therapeutics' (SGMO) "Buy" Rating Reiterated at HC Wainwright marketbeat.com - February 12 at 1:58 PM
	Sangamo Therapeutics Reports U.S. And European Regulatory Support For ST-920 markets.businessinsider.com - February 12 at 12:54 PM
	With 55% ownership of the shares, Sangamo Therapeutics, Inc. (NASDAQ:SGMO) is heavily dominated by institutional owners finance.yahoo.com - February 12 at 12:54 PM
	Sangamo Therapeutics Announces U.S. FDA Alignment on Abbreviated Pathway to Potential Approval and EMA Prime Eligibility for ST-920 in Fabry Disease finance.yahoo.com - February 12 at 12:54 PM
	Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Given Consensus Recommendation of "Hold" by Analysts marketbeat.com - February 8 at 3:35 AM
	Sangamo’s STAAR Study Shows Promise in Fabry Disease Treatment msn.com - February 7 at 6:47 PM
	Sangamo Therapeutics (NASDAQ:SGMO) Rating Reiterated by HC Wainwright marketbeat.com - February 6 at 9:06 AM
	Sangamo Therapeutics Announces Updated Phase 1/2 STAAR Study Data in Fabry Disease Showing Sustained Benefit and Differentiated Safety Profile finance.yahoo.com - February 5 at 9:44 PM
	Deep Dive Into Sangamo Therapeutics Stock: Analyst Perspectives (4 Ratings) markets.businessinsider.com - January 19 at 3:26 PM
	Bay Area biotech Sangamo puts entire Peninsula headquarters up for sublease bizjournals.com - January 16 at 6:19 PM
	2 low-priced gene therapy stocks to speculate on (SGMO) marketbeat.com - January 8 at 8:26 AM
	Sangamo Therapeutics Stock (NASDAQ:SGMO) Insider Trades benzinga.com - November 30 at 12:22 PM
	Truist Securities Downgrades Sangamo Therapeutics (SGMO) msn.com - November 8 at 2:07 AM
	Wells Fargo Downgrades Sangamo Therapeutics (SGMO) msn.com - November 6 at 10:55 PM
	Wells Fargo downgrades Sangamo, cites removal of key year-end catalyst msn.com - November 6 at 5:54 PM
	Where Sangamo Therapeutics Stands With Analysts markets.businessinsider.com - November 6 at 5:54 PM
	What 8 Analyst Ratings Have To Say About Sangamo Therapeutics markets.businessinsider.com - November 6 at 12:54 PM
	RBC Capital downgrades Sangamo as biotech moves to save cash msn.com - November 3 at 7:45 PM
	RBC Capital Downgrades Sangamo Therapeutics (SGMO) msn.com - November 3 at 7:45 PM
	Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Q3 2023 Earnings Call Transcript finance.yahoo.com - November 3 at 7:45 PM
	What To Know About RBC Capital's Downgrade of Sangamo Therapeutics markets.businessinsider.com - November 3 at 2:45 PM
	Biotech company Sangamo Therapeutics laying off 40% of workers, closing HQ msn.com - November 2 at 5:41 PM
	Sangamo Therapeutics (SGMO) Price Target Increased by 9.38% to 6.71 msn.com - November 2 at 2:40 AM
	Sangamo Therapeutics Announces Strategic Update and Reports Third Quarter 2023 Financial Results finance.yahoo.com - November 1 at 8:14 PM
	Sangamo Therapeutics Inc (SGMO) Announces Q3 2023 Financial Results and Strategic Update finance.yahoo.com - November 1 at 8:14 PM
	Sangamo Therapeutics earnings preview: what Wall Street is expecting markets.businessinsider.com - November 1 at 2:59 PM
	Sangamo Therapeutics (SGMO) May Report Negative Earnings: Know the Trend Ahead of Q3 Release finance.yahoo.com - October 26 at 12:55 PM
	Sangamo Therapeutics Announces Third Quarter 2023 Conference Call and Webcast finance.yahoo.com - October 25 at 8:16 PM

Get Sangamo Therapeutics News Delivered to You Automatically

Biden’s $374B Giveaway Into This Sector (Ad)

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

Click here for the full story

SGMO Media Mentions By Week

SGMO Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

SGMO
News Sentiment
▼
0.00

0.53
▲
Average
Medical
News Sentiment

SGMO News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

SGMO Articles
This Week
▼
0

2
▲
SGMO Articles
Average Week

Get Sangamo Therapeutics News Delivered to You Automatically

Related Companies and Tools

Related Companies:

Headlines Tools:

This page (NASDAQ:SGMO) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Sangamo Therapeutics (SGMO) News Today

SGMO Media Mentions By Week

SGMO Media Sentiment

SGMO News Coverage

Related Companies and Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info